HeartStent Corporation is developing a revolutionary minimally invasive products and procedures to treat patients with coronary artery disease. HeartStent pioneered and continues to refine a direct revascularization system for ventriculo-coronary artery bypass (VCAB). The direct revascularization device (DRD) is a permanent implant that directly connects the left ventricle to a coronary artery, thus reestablishing blood flow. HeartStent's proprietary technology and surgical method are well protected with twenty-two issued or pending U.S. patents and numerous foreign patents.

Our involvement: Business model, plan, management, fundraising